Legend Biotech

What can a full week dedicated to learning unlock for a global organization?    Our Legend Campus Learning Week brought colleagues from across the organization together to deepen their skills and invest in their growth, exploring business fundamentals, communication, innovation, and career development.    Through a mix of in-person, hybrid, and virtual sessions, teams tailored learning experiences to align with their roles and goals—fostering meaningful connections along the way.     This initiative reflects our ongoing commitment to investing in our people and strengthening our team as a whole. A special thank you to Alan Bash for his leadership and support as executive sponsor.     #CompanyCulture #Learning #ProfessionalDevelopment #Leadership

Our #Legendary teams were excited to welcome some very special visitors for Legend Biotech’s Take Your Child to Work Day at our New Jersey offices in Somerset and Raritan.    From science experiments to hands-on activities, it was a fun and meaningful day to share a glimpse of the work we do, and to celebrate the curiosity and creativity of the next generation of innovators. Thank you to everyone who helped make the day so memorable for our colleagues and their families. 📸Here are a few highlights from the day!    #TakeYourChildToWorkDay #LifeAtLegend #FutureOfScience

#LegendNews: Legend will announce its Q1 2026 #FinancialResults on Tuesday, May 12, at 8 a.m. ET.     Join our webcast for an update on our progress and recent milestones.    Register here:  https://lnkd.in/gekymAU    #FinancialResults #BiotechLeadership $LEGN 

Innovation only matters if patients can access it. This year, the Community Oncology Alliance’s annual conference in Orlando focuses on ensuring all patients with cancer can benefit from the latest advancements and treatments.     Legend Biotech is proud to be an Executive Platinum Exhibitor at #COA2026, supporting community oncology practices delivering advanced cancer care across the country.     📍 Booth 502 — stop by and meet us there!     Learn more: https://coaconference.com/     #CommunityOncology #InnovationInPractice #Biotech #CellTherapy 

At Legend Biotech, we’re investing in future commercial leaders who understand how strategy, execution, and access come together to drive meaningful impact for patients.     Today, we launched the Leadership Excellence & Acceleration Pathway Associate (LEAP)—a rotational program across Field Sales, Marketing, and Market Access that provides hands-on experience, cross-functional exposure, and mentorship to develop leaders who can drive execution with patients in mind.     As part of this launch, we are now accepting applications for the LEAP Associate role, designed for individuals motivated by learning, impact, and long-term leadership growth.     Open roles:  👉 Bridgewater (2 openings)  👉 Mid-Atlantic Region (1 opening)  👉 Midwest Region (1 opening)  👉 South Central Region (1 opening)  👉 West Region (1 opening)     📩 Contact Justin Kerno or Matt Mezer to learn more.    🔗 Apply: https://lnkd.in/e-M_RKbq     #LeadershipDevelopment #CommercialExcellence #BiotechCareers #TalentDevelopment #SalesLeadership

We’re headed to Tampa for #iwCART2026! Legend Biotech is excited to support the 8th International Workshop on CAR-T and Bispecifics as a Silver Sponsor. Don’t miss Session 17: CARs for Multiple Myeloma: 🗓️ April 25 | 1:30–3:00 PM 🎙️ Session Highlights: Rakesh Popat will present the latest updates from the CARTITUDE-4 study. We look forward to the interactive debates and expert panels that define this workshop! Explore the full program: https://iwcar-t.org #CellTherapy #CART #MultipleMyeloma #CancerResearch

#LegendNews: Research across Legend’s cell therapy portfolio will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting:    ✅ Rapid Oral: Preliminary results from an ongoing Phase 1 study of LB2102, a dnTGFBR2-armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNEC ✅ Poster: Outcomes in lenalidomide-refractory multiple myeloma patients responding to bridging therapy: CARTITUDE-4 cytogenetic sub-group analysis    These presentations reflect continued progress in advancing cell therapy innovation across hematologic malignancies and solid tumors.    Attending #ASCO26? Stop by booth #29155 to connect with the team and learn more about our presentations advancing cell therapy research.     #CART #CellTherapy #MultipleMyeloma #CancerResearch #SolidTumors #LungCancer

Most people haven’t heard of multiple myeloma. But for those living with it, the impact is real. That’s why closing the awareness gap matters. Earlier recognition and continued advancements in treatment can make a meaningful difference for patients. That progress is being driven by innovation in areas like cell therapy, helping move care forward and expand what’s possible worldwide. Learn more about our work in cell therapy: https://legendbiotech.com/ #MultipleMyeloma #BloodCancer #CellTherapy #CancerCare #InnovationInHealthcare

We asked our colleagues across Europe: What advice would you give to future team members? Their answer? Don’t wait. Take the step! At Legend Biotech, every role contributes to delivering advanced cell therapies to patients who need them most. You don’t need a perfect profile—just the desire to make a difference. Ready to make your work count? Explore our open roles in Europe: 🔗 https://lnkd.in/er44nTKS #WeAreLegend #LifeAtLegend #WeAreHiring #CareersInBiotech

Join Blood Cancer United on Thursday, April 16, at 3:00 p.m. ET for an educational webcast featuring Dr. Vu Nguyen (Kaiser Permanente) on how CAR‑T cell therapy is transforming blood cancer care.    📢 Topics include:  • The evolving role of CAR‑T cell therapy  • Side‑effect management  • What’s next for next‑generation CAR‑T therapies    As the role of CAR-T cell therapy continues to evolve, conversations like this help advance understanding of what’s next in treatment.    ✅ Sponsored by Legend Biotech & Johnson & Johnson Innovative Medicine    🔗 Register here:  https://lnkd.in/gAuWuref    #BloodCancer #CARTCellTherapy #OncologyEducation #Hematology